About Us

Lucenxia delivers a comprehensive care system for patients suffering from End Stage Renal Disease (ESRD), using the Peritoneal Dialysis (PD) modality to deliver better outcomes, greater values and more efficient economic returns. The system revolutionizes the treatment for ESRD patients, and proliferates the services nephrologists given to patients.

The far reaching Patient Care Management (PCM) system offered by Lucenxia will not only cater to more patients, relieving pressure on the scarce in-centre treatment resources, but will also improve the consistency and effectiveness of patient compliance and data collection.



In 2009, a group of medical technopreneurs gathered to explore opportunities to develop new innovations and technology in the field of Peritoneal Dialysis (PD). Their aim was not to seek a mere evolutionary innovation of existing technology, but to seek opportunities for innovations that would change the existing market space and practice. More importantly, they were deeply motivated to seek innovations that would yield significant improvements in patient outcomes and improve the quality of life for many renal patients affected by Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) in Malaysia.

This involved a comprehensive and multipronged study of the efficacy and challenges of existing treatment modalities, and the general PD landscape in the public and private healthcare spheres. Within the group, synergistic and broad subject-matter expertise enabled them to look holistically at the challenges at a national global perspective. It was clear that an opportunity for a truly revolutionary approach capitalizing on PD as a treatment modality was not only possible but realizable.

By 2010, the core group was already refining and implementing clinical, scientific, engineering, and economic/commercial models of their system and solution. For the first time, technology was driven by patient outcomes and patient-centricity became the bedrock of every decision. By early 2011, tests of a revolutionary Automated Peritoneal Dialysis (APD) machine were underway, and the infrastructure and network for sustained care was mapped. Lucenxia was born.